Equitec Proprietary Markets’s Jazz Pharmaceuticals JAZZ Stock Holding History

Equitec Proprietary Markets’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,688	Closed	-$428K	–	177
2022 Q4	$428K	Hold	2,688	–	–	0.14%	56
2022 Q3	$358K	Hold	2,688	–	–	0.09%	78
2022 Q2	$419K	Sell	2,688 -12	-0.4%	-$1.85K	0.12%	73
2022 Q1	$420K	Buy	2,700 +2,270	+528%	+$329K	0.09%	65
2021 Q4	$55K	Hold	430	–	–	0.01%	208
2021 Q3	$56K	Sell	430 -1,000	-70%	-$151K	0.01%	133
2021 Q2	$254K	Buy	+1,430	New	+$248K	0.08%	91

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Equitec Proprietary Markets's JAZZ Position: Q1 2023 in Review

Equitec Proprietary Markets sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 2,688 shares — an estimated $428K sold.

Equitec Proprietary Markets first reported a position in JAZZ in Q2 2021 and held it in 7 quarters. The position peaked at $428K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Equitec Proprietary Markets reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Equitec Proprietary Markets sold 2,688 Jazz Pharmaceuticals shares in Q1 2023, an estimated $428K.
Equitec Proprietary Markets first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Equitec Proprietary Markets's Jazz Pharmaceuticals position peaked at $428K in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Equitec Proprietary Markets's 13F filing for Q1 2023, filed 28 Apr 2023.